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Abstract
Background: Intervention with antiretroviral treatment (ART) and control of viral replication at the time of HIV-1
seroconversion may curtail cumulative immunological damage. We have therefore hypothesized that ART maintenance
over a very prolonged period in HIV-1 seroconverters could induce an immuno-virological status similar to that of HIV-1
long-term non-progressors (LTNPs).
Methodology/Principal Findings: We have investigated a cohort of 20 HIV-1 seroconverters on long-term ART (LTTS) and
compared it to one of 15 LTNPs. Residual viral replication and reservoirs in peripheral blood, as measured by cell-associated
HIV-1 RNA and DNA, respectively, were demonstrated to be similarly low in both cohorts. These two virologically matched
cohorts were then comprehensively analysed by polychromatic flow cytometry for HIV-1-specific CD4
+ and CD8
+ T-cell
functional profile in terms of cytokine production and cytotoxic capacity using IFN-c, IL-2, TNF-a production and perforin
expression, respectively. Comparable levels of highly polyfunctional HIV-1-specific CD4
+ and CD8
+ T-cells were found in
LTTS and LTNPs, with low perforin expression on HIV-1-specific CD8
+ T-cells, consistent with a polyfunctional/non-cytotoxic
profile in a context of low viral burden.
Conclusions: Our results indicate thatprolonged ART initiated at the time of HIV-1 seroconversion is associated with immuno-
virological features which resemble those of LTNPs, strengthening the recent emphasis on the positive impact of early
treatment initiation and paving the way for further interventions to promote virological control after treatment interruption.
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Introduction
Antiretroviral therapy (ART) is considered life-long once initiated
at the time of chronic HIV-1 infection. It remains unclear whether
we can change the course of the disease, decrease long-term
exposure to medication and promote control of viremia after
discontinuation of treatment initiated at the time of seroconversion
[1]. Residual reservoirs in long-lived CD4
+ T-cells, in particular, are
understood to be responsible for the virological rebound observed
after treatment interruption [2,3]. Previous studies in early infection
using various treatment durations have shown variable degrees of
immune preservation and decrease of the saturation of peripheral
viral reservoirs overtime.Wehave thereforehypothesized that a very
prolonged treatment period initiated at seroconversion might allow
the preservation/reconstitution of HIV-1-specific immunity as well
as a substantial decline in viral burden and promote a non-
progressive type of infection. Therefore, in order to help clarify this
issue,wehaveusedinthisstudyasacomparatortolong-termtreated
seroconverters (LTTS) a population of long-term non-progressors
(LTNPs) which remains disease-free and spontaneously controls
CD4
+ T-cell loss and viral replication in the absence of treatment.
We have concentrated our analysis on HIV-1-specific T-cells
which have been shown to play a substantial role in HIV-1
infection control. Previous studies have demonstrated an absence
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e18164of correlation between the magnitude of interferon-gamma (IFN-
c) production and viremia levels. As a result the emphasis has been
recently put on their qualitative rather than quantitative features
[4,5]. The term ‘‘polyfunctional’’ is therefore commonly used to
define a type of T-cell immune responses that, in addition to
typical effector functions such as cytotoxic activity and secretion of
IFN-c or tumor necrosis-alpha (TNF-a), also comprises distinct T-
cell populations able to secrete interleukin-2 (IL-2) and to retain
proliferative capacity [5,6,7,8]. A polyfunctional CD8
+ T-cell
profile has been associated with protective antiviral immunity in
several viral infections, including HIV-1 [6,9,10,11]. Cytotoxicity
is a further function by which CD8
+ T-cells mediate anti-tumor
and anti-viral activity [12,13,14] and we have recently shown that
perforin expression is the most powerful correlate of cytotoxic
function in human viral infections [15].
Studies have indeed demonstrated that HIV-1-specific CD8
+ T-
cells in LTNPs are functionally fit in terms of cytokine production
as well as proliferative and cytotoxic capacity, in contrast to what is
observed in chronic progressors [9,16,17,18,19,20]. Slow and
incomplete improvement of HIV-1-specific CD8
+ T-cell function-
ality in progressors has been noted when ART is initiated during
chronic infection, even when maintained for prolonged periods
[19,21]. As a rule treatment interruption has been associated with
viral rebound which suggests that residual functional immunolog-
ical defects are still present after many years of treatment-induced
aviremia in chronically infected patients [21]. Recent studies have
indeed shown that polyfunctionality, proliferation and cytotoxicity
capacities are not recovered to the same extent as in LTNPs when
ART is initiated during the chronic stage of the infection [19,22].
However, preservation and enhanced reconstitution of these
immune functions as well as a substantial decrease of viral
reservoirs may occur with an early and prolonged treatment
intervention able to produce at the time of acute infection a rapid
viremia decline and subsequent prolonged aviremia.
In this study we have compared HIV-1-specific CD4
+ and
CD8
+ T-cell functionality, immune activation, HIV-1 reservoirs
and residual replication in peripheral blood of LTTS with those of
LTNPs. We have measured cell-associated HIV-1 DNA and RNA
levels to quantify reservoirs and residual viral replication,
respectively and assessed CD8
+ T-cell immune activation by
CD38
+ expression. HIV-1-specific CD4
+ and CD8
+ T-cell
responses (initially screened by IFN-c ELISpot assay) were
analysed by polychromatic intracellular cytokine staining (ICS)
in order to assess polyfunctionality as defined by the production of
multiple cytokines (IFN-c, IL-2 and TNF-a) and the ex-vivo
perforin expression by HIV-1-specific CD8
+ T-cells.
Interestingly enough, similarly low levels of cell-associated HIV-
1 DNA and RNA as well as CD8
+/CD38
+ T-cells were detected
in peripheral blood in the two subject groups. We have also
demonstrated the presence of highly polyfunctional HIV-1-specific
CD4
+ and CD8
+ T-cells in all LTTS and LTNPs and little
perforin expression on HIV-1-specific CD8
+ T-cells in both
cohorts.
Our study design allowed overcoming the recurrent bias of the
different viral burden present in previous studies which have
compared HIV-1 with other persistent human viral infections (e.g.
CMV, EBV vs. HIV) or cohorts of HIV-1 progressors vs. non-
progressors for immune correlates of viral control. We had in
contrast the unique opportunity to compare two cohorts of HIV-1-
infected subjects with a strikingly similar viral burden. This is of
relevance since immune correlates of virological control are known
to be associated with the extent of viral burden [5].
Our results therefore raise the possibility of HIV-1-specific T-
cell immune preservation/reconstitution with early and prolonged
ART in a context of low viral burden in peripheral blood and
provide a detailed comparison of HIV-1-specific T-cell profile in
subjects with similar viral burden in ART-induced and spontane-
ous control of viral replication. These data should guide further
therapeutic studies in HIV-1 seroconverters to investigate newer
therapeutic compounds aimed at further decreasing viral reser-
voirs and test the possibility of long-term control of viremia after
treatment discontinuation [23]. The comprehensive information
in terms of HIV-1-specific T-cell functional profile and viral
reservoirs in LTNPs provided here should also increase our
understanding of correlates of viral control and help contribute to
vaccine development.
Methods
Study population
The study included a total of 35 patients who were prospectively
enrolled into 2 cohorts between March 2007 and March 2008.
Their characteristics are described in Table 1.
The first cohort included 20 long-term ART-treated serocon-
verters (LTTS) who had chosen to initiate treatment at the time of
HIV-1 seroconversion and had been followed up in the same
treatment centre since diagnosis. They were selected from the
Royal Free Hospital (RFH) cohort of seroconverters at the Ian
Charleson Day Care Centre (ICDC) using our HIV database on
the basis of the following inclusion criteria: (a) ART for at least 4
years with no treatment interruption; (b) long-term aviremia (,50
HIV-1 RNA copies/mL) and (c) an absence of treatment failure
defined by a viral load above 400 HIV-1 RNA copies/mL.
Seroconversion to HIV-1 was defined by: (a) negative HIV-1
antibody by ELISA and evidence of HIV-1 viremia $5,000 HIV-
1 RNA copies/mL plasma and/or (b) incomplete HIV Western
Blot with #3 bands and/or detuned assay with a value of ,0.6 for
clade B patients. At the time of seroconversion, median CD4
+ T-
cell count was 474 (range: 187–1033) and plasma viral load
750.000 HIV-1 RNA copies/mL (range: 38.300–7.500.000).
Duration of ART was calculated from the day of initiation of
ART until the time of sampling. Treatment (2 non-nucleoside
analogues inhibitors of the HIV-1 reverse transcriptase and 1
boosted inhibitor of HIV-1 protease) was initiated shortly after the
diagnosis of HIV was made (median time from diagnosis to
treatment initiation: 13 days).
The second cohort included 15 long-term non-progressor
subjects (LTNPs) recruited at the Ian Charleson Day Centre
(ICDC) (n=9) and Haemophilia Centre (n=2) at the RFH in
London using the centre’s HIV database as a reference, and
referrals from University College Hospital, London (n=1), North
Middlesex Hospital, London (n=1), University Hospital of Wales,
Cardiff (n=1) and at Victoria Hospital, Blackpool (n=1) in the
UK. Inclusion criteria were: (a) $7 years of documented HIV-1
infection; (b) viremia ,1000 HIV-1 RNA copies/mL plasma in
.90% of measurements; (c) $500 CD4
+ T-cells/mm
3 in $90%
of measurements; (d) absence of AIDS-defining conditions; (e)
ART-naive except for zidovudine use for the prevention of
mother-to-child transmission (n=2). Patients’ medical files were
reviewed in order to confirm inclusion criteria. Patient character-
istics are described on Table 1.
As shown in Table 1, the 2 cohorts were matched for major
clinical and laboratory parameters. Men who had sex with men
were in a majority in both cohorts although females were better
represented in LTNPs. Both cohorts were similar in terms of HIV-
1 viral load and CD4
+ T-cell counts at the time of blood sampling.
Median CD4
+ T-cell count was 783 (range: 433–1648) and 800
(range: 567–1412) for LTNPs and LTTS, respectively (P=0.29).
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ml at the time of sampling except for 4 LTNPs (381, 240, 636, 130
HIV-1 RNA copies/mL). Therefore, the vast majority of LTNPs
also fulfilled the criteria for elite controllers [24]. Median duration
of infection at the time of sampling was 13 years (range: 7–25) for
LTNPs and 6 years (range: 4–7) for LTTS.
Ethics Statement
Informed written consent was obtained from all subjects. The
study was approved by the Royal Free Hospital and NHS ethics
committees and the Institutional Review Board of the Centre
Hospitalier Universitaire Vaudois.
Blood sampling and PBMC isolation and storage
A single blood sample was performed at the ICDC at the RFH
in London for research purposes. Processing of EDTA samples for
virological and immunological analysis was performed at the
Department of Immunology at the RFH within 3 hours of
venopuncture. Peripheral blood mononuclear cells (PBMCs) were
isolated by Ficoll-Paque density gradient centrifugation from
heparinized blood and stored in 7.5% DMSO in liquid nitrogen.
We also performed on the day of blood sampling routine full
blood count, biochemistry, hepatitis B and C serology, CD4
+ and
CD8
+ T-cell counts, CD4
+/CD8
+ T-cell count ratio, CD8
+/
CD38
+ T-cell absolute counts and percentages, HIV-1 viremia
and viral clade and HLA class I determination. Levels of CD8
+/
CD38
+ T-cells were quantitated according to a previously
published method [25]. HIV-1 pol gene sequences for codons 1–
99 of the protease and 1–335 of reverse transcriptase (RT) were
obtained from whole EDTA blood samples using the Vircoseq
TM
HIV-1 genotyping system (Abbott Laboratories/Celera Diagnos-
tics, USA) according to the manufacturer’s instructions. Sequences
were analysed with a 3100-Avant Genetic Analyzer (Applied
Biosystems, UK) and edited using Seqscape v2.5 (Applied
Biosystems, UK). Subtypes were assigned by phylogenetic analysis
using the software MEGA v4 [26] and by comparing to known
reference HIV-1 sequences derived from the Los Alamos database
[27].
HLA class I genotyping
High-resolution sequence-based typing was carried out for
HLA-A and HLA-B, as previously described [28]. Briefly, generic
PCR co-amplification of both maternal and paternal alleles was
carried out to create PCR products specific for these loci. Cycle
sequencing using the Dye terminator method was then carried out
using ABI PrismH BigDyeH Terminator v3.1 chemistry. Sequenc-
ing was targeted at exons 2, 3 and 4. The results generated were
compared with previous LuminexH typing to remove any
ambiguous combinations not seen by this technique.
HLA-C genotyping was performed at an intermediate resolu-
tion level using LABTypeH SSO Typing Test according to the
manufacturer’s instructions. Data were analysed on a LuminexH
100 flow analyser.
Synthetic peptides used in IFN-c ELISpot and
polychromatic flow cytometry assay (ICS)
All peptides used in this study were HPLC purified (.80%
purity). We selected 191 HIV-1-derived epitopes (9/10-mers)
covering different regions (Gag, Env, Pol, Nef, Tat, Rev, Vpr, Vpu
and Vif) of HIV-1 from consensus strain IIIB. Only optimal CD8
+
Table 1. Subjects Characteristics.
LTTS
A (n=20) LTNPs
A (n=15) P value (a=0.003)
Males (%) 19 (95) 11 (73) 0.14
Age* (range) 40 (29–59) 41 (27–67) 0.5
Caucasian (%) 19 (95) 14 (93) 1
MSM
B (%) 18 (90) 8 (53) 0.02 (N.S.)
C
HTS
B (%) 2 (10) 5 (33) 0.11
HAEM
B (%) 0 (0) 2 (13) 0.18
Years of infection* (range) 6 (4–7) 13 (7–25) n.a.
D
CD4
+ T-cells* (cells/mL; range) 800 (567–1412) 783 (433–1648) 0.29
CD4
+/CD8
+ T-cell ratio* (range) 1.1 (0.65–3.70) 1.2 (0.31–1.90) 0.06
CD8
+/CD38
+ T-cells* (x10
9cells/L; range) 0.05 (0.008–0.274) 0.06 (0.016–0.534) 0.23
CD8
+/CD38
+ T-cells* (%; range) 7 (3–25) 6 (3–30) 0.28
pVL
E* (HIV-1 RNA copies/mL) all ,50 11 ,50, 4 ,1000 n.a.
D
Cell-associated HIV-1 RNA* (copies/10
6 PBMCs; range) 3.9 (0–36) 5.8 (0–10.3) 0.16
Cell-associated HIV-1 DNA* (copies/10
6 PBMCs; range) 47.7 (4.8–583.2) 19.7 (0.5–295.5) 0.10
Patients with HLA-B*5701 allele (%) 1 (5) 4 (27) 0.14
Patients with HLA-B*5701, -B*2705, -B*5801,
-B*5101, -B*1302 alleles (%)
5 (25) 6 (40) 0.45
Patients with HLA-B*3503, -B*5301, -B*1801 alleles (%) 3 (15) 2 (13) 1
ALTTS, long-term treated HIV-1 seroconverters; LTNPs: HIV-1 long-term non-progressors.
BMSM, men-having-sex-with-men; HTS, heterosexuals; HAEM, haemophiliacs.
CN.S., not statistically significant after Bonferroni correction for multiple testing (the cut-off for statistical significance is 0.003).
Dn.a, not applicable.
EpVL, plasma viral load.
*Median values at time of sampling.
doi:10.1371/journal.pone.0018164.t001
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[29]. Fine epitope mapping was thus performed on the predicted
HLA class I genotype according to Los Alamos database and
patient HLA class I genotype. The 191 optimal CD8
+ T-cell
epitopes were tested individually in the polychromatic intracellular
cytokine staining (ICS) assay and organized into 28 pools of
multiple peptides based on a 14614 matrix such that each epitope
was present in precisely 2 pools [30]. Furthermore, a pool of 105
peptides (15-mers overlapping by 11 amino acids (aa) encompass-
ing the Gag protein (aa gag 1-gag 432) of HIV-1 from consensus
strain IIIB was used in ICS in order to evaluate the response to this
protein by the CD4
+ T-cell subset. In addition, a pool of peptides
(n=23) most frequently recognized in Cytomegalovirus, Epstein
Barr Virus and Flu (pool CEF) infections was used to assess the
functional profile of non-HIV-specific CD8
+ T-cell responses [31].
Interferon-gamma (IFN-c) enzyme-linked immunospot
(ELISpot) assay
Initial screening for HIV-1-specific CD8
+ T-cell responses in the
2 study cohorts was performed by IFN-c ELISpot assay. The assay
was conducted on cryopreserved peripheral blood mononuclear
cells (PBMCs) using Becton Dickinson (BD, San Diego, USA)
human IFN-c ELISpot kit according to the provided protocol.
Briefly, PBMCs were plated at 10
6 cells/well after 4–6 hour resting.
Stimulation was performed in triplicates in the presence of 1 mg/
well of peptide (from the panel of 191 HIV-1 selected peptides
organized in a matrix pool) or 200 ng/well of staphylococcal
enterotoxin B (SEB) used as a positive control. In addition, a
negative control with medium alone was always included in each
test. Plates were stored at 37uC in a 5% CO2 incubator overnight,
washed, and coated with detection antibody for 2 hours at room
temperature. They were again washed and coated with avidin-
peroxidase for 1 hour at room temperature. Plates were then
washed and developed by addition of AEC (3-Amino-9-ethyl-
carbazole) substrate. Responses were expressed as net spot-forming
units (SFU) per 10
6 PBMCs. The following criteria were used to
define the technical validity of the assay and positive responses: (a)
The number of spot forming units (SFU)/10
6 PBMCs in the assay
background (unstimulated PBMCs) had to be ,50 and the positive
control responses to SEB .500 SFU/10
6 PBMCs; (b) Responses
were considered positive when $fourfold above background and
$55 SFU/10
6 PBMCs. HIV-1-specific T-cell responses were
further characterized using polychromatic intracellular cytokine
staining (ICS) in responders with IFN-c ELISpot responses in the
range of 100 SFU/10
6 cells or above.
Antibodies (Abs)
The following Abs were used in the ICS assay: CD8-PB, CD4-
ECD, IFN-c-APC, TNF-a-PECy7 and IL-2-PE (BD, San Diego,
USA), perforin-FITC (Biolegend, San Diego, USA) and CD3-
APCCy7 (Invitrogen, Carlsbad, USA).
Polychromatic intracellular cytokine staining (ICS)
Cryopreserved PBMCs were thawed and rested overnight in
R10 media (RPMI Glutamax-1 containing 10% heat-inactivated
fetal calf serum) at a concentration of 10
6 cells/mL. The following
day 1–2610
6 cells were stimulated for 6 h in 1 ml of R10 media in
the presence of Golgiplug [1 ml/ml, Becton Dickinson (BD), San
Diego, CA], purified soluble anti-CD28 Ab (0.5 mg/ml, BD San
Diego, CA) and 1 mg/ml of peptide [32]. An unstimulated (R10
only) and positive control (SEB 200 ng/ml) were included in each
assay. At the end of the stimulation period, cells were washed,
stained for dead cells using the Aqua LIVE/DEAD stain kit
(Invitrogen), permeabilized (Cytofix/Cytoperm, BD) and then
stained at RT for 30’ with CD3, CD4, CD8, IFN-c, TNF-a, IL-2
and, when indicated, perforin. Cells were then fixed and acquired
on an LSR SORP flow cytometer (BD). Data were analysed using
FlowJo software (version 8.8.2; Tree Star). For the analysis of
polyfunctionality, the FlowJo Boolean Gate Platform was used to
create 8 and 16 patterns of responses for the 3 or 4 tested
functions, respectively. The gating scheme used for all ICS assays
performed is shown in Data S1. Data were plotted and further
analysed with SPICE software (version 4.2.3; from M. Roederer,
National Institutes of Health, Vaccine Research Center, Bethesda,
MD). All reported values have been corrected for background.
The number of lymphocyte-gated events ranged between 6610
5
and 1610
6 in the flow cytometry experiments. The mean of the
background in the unstimulated controls +2 standard deviations
never exceeded 0.05%. An ICS result to be considered positive
had display more than 0.05% of cytokine-positive cells and to be
$threefold above background.
Virological studies
Cell-associated HIV-1 RNA and DNA levels were quantitated
using a previously published method [33] with a limit of detection of
3 copies/10
6 PBMCs. We have reported levels of copies per million
PBMCs as in other studies and not per CD4
+ T-cellsas CD4
+ T-cell
counts in both cohorts were high and there was no predicted
dilution effect in the absence of variation in CD4
+ T-cell counts.
Statistical analysis
Statistical significance (P values) of the results was calculated by
two tails student t-test using either Excel (Microsoft, Redmond,
WA) or SPICE 4.2.3. Correlations among variables were tested by
simple regression analysis. Proportions were compared with
Fisher’s exact test using GraphPad Prism version 3.0 (GraphPad
Software, San Diego, CA, USA). The level of significance was set
at P,0.05 and Bonferroni adjustment of P-values was applied in
case of multiple testing.
Results
HLA class I analysis in LTTS and LTNPs
Several lines of evidence have stressed in recent years the
importance of HLA class I genotype in predicting progression
[34,35,36] with certain alleles associated with a slower course of
the infection. Therefore, in order to exclude large differences in
the genetic background of our 2 cohorts, we assessed the HLA
class I genotype in all study patients. High- and intermediate-
resolution HLA class I typing was performed as described in the
method section for loci A and B, and for locus C, respectively. As
shown in Table 1, when evaluating the frequency of HLA alleles
known to be associated with slow (HLA-B*5701/02/03, *2705,
*5801, *5101, *1302) or rapid (HLA-B*5802, *3502/03, *5301,
*1801) disease progression [37], we found a trend towards a higher
frequency of HLA-B*5701 alleles in LTNPs as compared to LTTS
(27% of LTNPs vs. 5% of LTTS were B*5701
+; P=0.14) which
confirmed the previously described enrichment of this allele in
LTNPs and showed that this was the only major difference in
terms of HLA class I genotype between the two cohorts studied.
Similarly low levels of HIV-1 reservoirs, residual
replication and CD8
+/CD38
+ T-cells in LTTS and LTNPs
peripheral blood
Residual viral replication and persistence of HIV-1 in long-lived
reservoirs in resting CD4
+ T-cells are associated with viral
Immuno-Virological Effects of Prolonged Early ART
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to eradication [3,38,39,40,41,42]. Cell-associated HIV-1 RNA
and DNA have been detected in the resting CD4
+ T-cell
compartment in the peripheral blood of the majority of infected
individuals with undetectable viremia while on ART [43]. Their
levels have been used in several previous studies to quantify the
saturation of viral reservoirs and residual viral replication in
peripheral blood in aviremic subjects, respectively. Cell-associated
HIV-1 DNA levels have been correlated to the extent of
virological rebound after ART discontinuation in subjects with
treatment initiation during acute or chronic infection [44,45].
Recent studies have suggested that early treatment initiation may
accelerate HIV-1 decay both in blood and gut-associated
lymphoid tissue [42,46,47]. Therefore, in order to better quantify
viral burden in our two cohorts, we have used these two further
virological markers in addition to plasma viremia.
When comparing cell-associated HIV-1 DNA and RNA
between the two cohorts, we found that all study subjects had
similarly low levels. Results are shown in Table 1. The median
number of copies of cell-associated HIV-1 DNA per 10
6 PBMCs
was 47.7 (range 583.2–4.8) and 19.7 (range 295.5–0.5) in LTTS
and LTNPs, respectively (P=0.10). Median HIV-1 RNA levels
were 3.9 (range 45.8–0.7) and 5.8 copies per 10
6 PBMCs (range
10.3–1.4) in LTTS and LTNPs (P=0.16), respectively. Altogether
these results show strong similarities between the two cohorts using
virological markers aimed at further assessing viral reservoirs and
residual replication in peripheral blood in these aviremic subjects.
T-cell immune activation is known to play an important role in
HIV pathogenesis and is linked to CD4
+ T-cell decline and disease
progression [48,49]. Although CD38 can also be expressed on the
surface of thymocytes and naı ¨ve T-cells, it is widely used as an
activation marker in HIV infection. We have previously described
that early initiation of ART at seroconversion is associated with
decreasing levels of CD8
+/CD38
+ T-cells [25]. The expression of
CD38 on HIV-1-specific CD8
+ T-cells has been shown to be low
in LTNP cohorts and similar to that found in successfully treated
patients [48,50]. However, comparative data between LTTS and
LTNPs for CD8
+/CD38
+ T-cells are not available and this marker
could be an indicator of the extent of immune reconstitution which
is taking place with prolonged ART initiated at seroconversion.
In this study, we were able to show further similarities between
the two cohorts in terms of CD8
+ T-cell activation as measured by
CD38 expression. Both displayed normal levels of CD8
+/CD38
+
T-cells (normal range for absolute count: 0.2–0.8610
9/L and
percentage: 3–22% of lymphocytes). Median absolute CD8
+/
CD38
+ T-cell counts and percentages were 0.06 and 0.05610
9/L
(P=0.23) and 6% and 7% (P=0.28) for LTNPs and LTTS,
respectively.
Similar magnitude and functional profile of HIV-1 Gag-
specific CD4
+ T-cell responses in LTTS and LTNPs
We wanted to investigate in details the effect of prolonged
treatment started in early infection on HIV-1-specific CD4
+ T-
cells as these cells play a central role in sustaining CD8
+ T-cell
functions. It has been previously demonstrated that HIV-1-specific
CD4
+ T-cell functional profile is driven by the level of antigen
exposure: the cytokine producing pattern is skewed towards IFN-c
only production in viremic individuals but can be rescued by ART
intervention [51,52].
It was thus important to further characterize HIV-1-specific CD4
+
T-cell functional profile in a seroconverter cohort with long-term
treatment and to compare it with LTNPs. Moreover, our LTTS and
LTNP cohorts were shown to be highly homogenous for low viral
burden thus providing the opportunity to compare the HIV-1-specific
CD4
+ T-cell functional profile in conditions of ART-induced vs.
spontaneous controlled viremia. HIV-1-specific CD4
+ T-cells were
therefore characterized in a randomly selected subgroup of 25 subjects
( 1 6L T T Sa n d9L T N P s )f o rI F N - c,T N F - a and IL-2 production
upon stimulation with the Gag peptide pool. A representative example
of results for each cohort is shown in Figure 1A.
We demonstrated that Gag-specific CD4
+ T-cell responses were
detected in all subjects. When quantifying the amount of IFN-c,
TNF-a and IL-2-producing cells upon stimulation with the Gag
peptide pool, LTTS and LTNPs showed overall similar levels as
shown in Figure 1B. After subtraction of the background, the total
cytokine response was 0.28% and 0.33% of CD4
+ T-cells in LTTS
and LTNPs, respectively (P=0.28). The mean percentage of Gag-
specific CD4
+ T-cells producing IFN-c was 0.15% (range 0.01%–
0.61%) and 0.21% (range 0.03%–0.46%) in LTTS and LTNPs,
respectively (P=0.20). Values in LTTS and LTNPs for TNF-a
were 0.24% (range 0.02%–0.63%) and 0.35% (range 0.05%–
0.70%) (P=0.10) and for IL-2 0.12% (range 0.02%–0.27%) and
0.19% (range 0.04%–0.51%) (P=0.08).
We next analysed the Gag-specific CD4
+ T-cell functional
profile based on its ability to secrete one or more cytokines. As
shown in Figure 1C, a similar polyfunctional profile, as defined by
the presence of HIV-1-specific CD4
+ T-cells producing simulta-
neously more than one cytokine was present. Polyfunctional CD4
+
T-cell populations accounted for more than 50% of the total
response in both cohorts (61% in LTTS and 64% in LTNPs;
P=0.39). In particular, the mean percentage of the ‘triple positive’
population, i.e. the cells producing simultaneously IFN-c, IL-2 and
TNF-a, was 30% (range 11%–49%) and 33% (range 3%-69%) in
LTTS and LTNPs, respectively (P=0.32).
We were therefore able to demonstrate robust and polyfunc-
tional HIV-1-Gag-specific CD4
+ T-cell responses of similar
intensity and functional profile in both cohorts.
Higher breadth and magnitude of HIV-1-specific CD8
+ T-
cell responses in LTNPs as compared to LTTS
Robust HIV-1-specific CD8
+ T-cells have been described in
LTNPs in contrast to those found in aviremic patients receiving
effective ART during chronic infection [18,22,53,54]. In order to
clarify whether early treatment initiation could lead to a different
pattern of responses than the one found in treated chronic
infection, we initially screened our subjects for HIV-1-specific
CD8
+ T-cell responses by IFN-c ELISpot assay using the epitope
matrix pool described in the method section. High levels of IFN-c-
producing T-cells were detected in all subjects but the breadth and
magnitude of responses, however, differed between the two
cohorts. A higher mean number of responding pools (14 versus
8; P=0.0005) and SFU/10
6 PBMCs (665 versus 426; P=0.00001)
was found in LTNPs as compared to LTTS.
We then performed fine epitope mapping by matching subjects’
HLA class I genotype with ELISpot assay results according to the
Los Alamos database of HLA class I restriction. HIV-1-specific T-
cell responses were further characterized in patients with IFN-c
ELISpot responses in the range of 100 SFU/10
6 cells or above by
ICS analysis for IFN-c, IL-2 and TNF-a production upon
stimulation with the optimal mapped CD8
+ T-cell peptides. Thus,
103 epitope-specific CD8
+ T-cell responses (63 from LTNPs and
40 from LTTS) were analysed by ICS. Representative examples of
these responses are shown in Figure 2A and B.
In line with the ELISpot data, we found a higher breadth of
responses in LTNPs by ICS analysis with LTTS and LTNPs
subjects targeting a median of 2 (range 1–5) and 5 (range 1–9)
epitopes, respectively (P=0.001). These results were still signifi-
cant when HLA-B*5701
+ subjects were removed from the
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LTNPs was independent of the HLA-B*5701 imbalance between
the 2 cohorts.
Alongside the higher breadth, the increased magnitude of
responses found in LTNPs by ELISpot assay was confirmed by
ICS analysis, although not reaching statistical significance, when
we determined the percentage of IFN-c-, TNF-a- and IL-2-
producing CD8
+ T-cells following stimulation with specific
peptides (Figure 3A). After subtraction of the background, the
total cytokine response was 0.37% and 0.50% of HIV-1 specific
CD8
+ T-cells in LTTS and LTNPs, respectively (P=0.06). The
mean percentage of epitope-specific IFN-c-producing CD8
+ T-
cells was 0.34% (range 0.03%–1.18%) and 0.47% (range 0.04%–
1.85%) in LTTS and LTNPs, respectively (P=0.07). Respective
values in LTTS and LTNPs for TNF-a production were 0.31%
(range 0%–1%) and 0.40% (range 0.02%–1.51%) (P=0.08) and
for IL-2 production 0.19% (range 0.01%–0.75%) and 0.24%
(range 0%–1.30%) (P=0.11).
We next determined whether HIV-1-specific CD8
+ T-cell
responses targeting viral proteins or epitopes shown to be
associated with viral control (‘‘favourable epitopes’’) [55,56,57]
and those restricted by the HLA-B*5701 allele showed different
levels of cytokine production. Gag responses were shown to
contribute substantially to the higher magnitude of responses
found in LTNPs. As shown in Figure 3B, IFN-c, TNF-a and IL-2
production by CD8
+ T-cells upon stimulation with Gag peptides
was significantly higher in LTNPs than in LTTS. After subtraction
of the background, the mean percentage of Gag-specific CD8+ T-
cells producing IFN-c was 0.22% and 0.54% in LTTS and
LTNPs, respectively (P=0.01). Respective values in the LTTS and
LTNP groups for TNF-a were 0.18% and 0.46% (P=0.01) and
for IL-2 0.11% and 0.26% (P=0.02). In contrast, CD8
+ T-cell
responses targeting proteins other than Gag were of similar
intensity in both cohorts (data not shown). When comparing
between the two cohorts responses targeting ‘‘favourable epitopes’’
(Data S2 A) and HLA-B*5701-restricted responses (Data S2 B), we
found similar levels of IFN-c, TNF-a and IL-2 production which
matched those observed for CD8
+ T-cell responses targeting
epitopes other than the ‘‘favourable’’ ones and which were
restricted by HLA class I alleles other than HLA-B*5701 (data not
shown). However, these analyses were limited by the small number
of responses targeting ‘‘favourable epitopes’’ (n=2) and HLA-
B*5701-restricted responses (n=2) in LTTS. In addition, we
found that the majority of ‘‘favourable epitope’’-targeting (5 out of
7) and HLA-B*5701-restricted responses (7 out of 13) in LTNPs
were directed towards the Gag region and were among the
strongest responses that we could observe.
In line with a recent report [58], the trend for stronger HIV-1-
specific CD8
+ T-cell responses and lower cell-associated HIV-1
DNA in LTNPs as compared to LTTS resulted in a higher ratio of
these 2 parameters in LTNPs (0.45 vs. 0.03; P=0.02). However,
the statistically significant difference was lost when we analysed the
ratio of Gag-specific CD8
+ T-cells and cell-associated HIV-1 DNA
(0.33 vs. 0.02; P=0.06).
Of interest, we found that the trend towards a lower magnitude
of CD8
+ T-cell responses observed in LTTS was HIV-1 specific.
Figure 1. Functional cytokine profile of HIV-1 Gag-specific CD4
+ T-cells. (A) Shown are two representative flow cytometry profiles of Gag-
specific CD4
+ T-cell responses from a LTTS (dot plots on the left) and a LTNP (dot plots on the right) subject. The production of IL-2, TNF-a and IFN-c
was measured upon 6 hours of in vitro stimulation with the Gag peptide pool. (B) Cumulative data (mean6SE) on the percentage of IFN-c-, IL-2- and
TNF-a-producing HIV-1 specific CD4
+ T-cells following stimulation with the Gag peptide pool. (C) Cumulative data of the simultaneous analysis of IFN-
c, IL-2 and TNF-a production. All possible combinations of IFN-c, IL-2 and TNF-a production are shown on the x axis, whereas the percentage of the
various cytokine-producing cell subsets within HIV-specific CD4
+ T-cells is shown on the y axis. Pie charts summarize the data, and each slice
corresponds to the proportion of virus-specific CD4
+ T-cells positive for a given combination of T-cell functions. LTTS: long-term treated HIV-1
seroconverters; LTNPs: HIV-1 long-term non-progressors.
doi:10.1371/journal.pone.0018164.g001
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suitable numbers of PBMCs were available, we characterized
CD8
+ T-cell responses based on IFN-c, TNF-a and IL-2
production upon stimulation with CMV, EBV and Flu peptides
(CEF pool). Our results showed that LTTS displayed stronger
CD8
+ T-cell responses than LTNPs (data not shown).
Overall, these data show that the breadth and magnitude of
HIV-1-specific CD8
+ T-cell responses differed between the two
groups. Although LTTS showed strong virus-specific CD8
+ T-cell
responses, these were more robust and diverse in LTNPs.
Frequency of distinct optimal HIV-1-specific CD8
+ T-cell
epitope recognition
We have shown a wider breadth of HIV-1-specific CD8
+ T-cell
responses in LTNPs and next investigated whether this was
matched by a different frequency of epitope-targeting.
We first assessed whether viral proteins were targeted with
similar frequencies in the two cohorts and found a trend towards
LTNPs targeting more Gag and RT-Pol epitopes and LTTS
targeting more Env epitopes. However, the frequencies of
recognition were too low to allow solid comparisons between the
two groups.
We next evaluated the frequency of ‘‘favourable epitopes’’
targeted among all recognized HIV-1-specific CD8
+ T-cell
epitopes in both cohorts. Four ‘‘favourable epitopes’’ were
included in the panel of 191 optimal CD8
+ T-cell epitopes used
in the ICS assay: KK10-B*2705, TW10-B*5701, HW9-B*5701
and DA9-B*1402. We found that these epitopes were among the
most commonly recognized ($40%) in both cohorts. The
frequency of recognition was 67%, 60%, 40% and 100% for
KK10-B*2705, TW10-B*5701, HW9-B*5701 and DA9-B*1402,
respectively. Moreover, LTNPs recognized more frequently the
‘‘favourable epitopes’’ than LTTS (13% vs. 5%; P=0.24). This
difference was mainly explained by the higher frequency of the
HLA-B*5701 allele in LTNPs since 50% (2 out of 4) of the
‘‘favourable epitopes’’ tested in the ICS assay were HLA-B*5701-
Figure 2. Flow cytometry profiles of HIV-1-specific CD8
+ T-cells. (A) Shown are two representative flow cytometry profiles of HIV-1-specific
CD8
+ T-cell responses from two LTTS subjects: left panels from subject #LED-020 (stimulation with a gp41 epitope, aa 46–54) and right panels from
subject #GOV-005 (stimulation with a nef epitope, aa 73–82). (B) Shown are two representative flow cytometry profiles of HIV-1-specific CD8
+ T-cell
responses from two LTNP subjects: left panels from #DEN-015 (stimulation with a nef epitope, aa 116–124) and right panels from #AAC-002
(stimulation with a p24 epitope, aa 162–172). IL-2, TNF-a and IFN-c production was measured upon 6 hours of in vitro stimulation with optimal HIV-1
peptides. LTTS: long-term treated HIV-1 seroconverters; LTNPs: HIV-1 long-term non-progressors.
doi:10.1371/journal.pone.0018164.g002
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HLA-B alleles were more frequently recognized than those
restricted by HLA-A (P=0.005) or -C alleles (P=0.066).
We observed that in HLA-B*5701
+ patients HIV-1-specific
CD8
+ T-cell responses were largely focused on epitopes restricted
by this allele. Among the 5 HLA-B*5701
+ patients (4 LTNPs and
1 LTTS), 3 had 100%, 1 had 80% and 1 had 60% of CD8
+ T-cell
responses targeting epitopes restricted by this allele. These data
confirm previous reports [36,59] of the preferential targeting of
HLA-B*5701 restricted epitopes in patients positive for this allele.
Similar levels of polyfunctional HIV-1-specific CD8
+ T-cell
responses in both cohorts
A growing body of evidence indicates that the independent
assessment of single functions may not be particularly informative,
whereas the simultaneous analysis of multiple parameters can
provide a more accurate picture of CD8
+ T-cell functionality. In
particular, polyfunctional CD8
+ T-cells (i.e. CD8
+ T-cells
exhibiting simultaneously multiple functions) have been associated
with protective antiviral immunity and the control of viral
infections [6,9,10,11]. In the present study we had the unique
opportunity to compare the level of HIV-1 specific CD8
+ T-cell
polyfunctionality between these two cohorts which were matched
for viral burden.
We therefore analysed and compared the HIV-1-specific CD8
+
T-cell functional profile in LTTS and LTNPs by simultaneously
analyzing IFN-c, IL-2 and TNF-a production in the previously
characterized 103 epitope-specific CD8
+ T-cell responses. Each
response was characterized for the presence of 8 possible different
types of cell populations with various patterns of cytokine
production. As shown in Figure 4A, both cohorts showed similar
proportions of HIV-1-specific CD8
+ T-cell populations with a
given pattern of cytokine production (all P.0.05) and a similar
global functional profile (P=0.5; Figure 4B).
We next focused on the triple-positive cell population (i.e. CD8
+
T-cells producing simultaneously IFN-c, IL-2 and TNF-a) and
restricted the analysis of polyfunctionality to this subset. As shown
in Figure 4A, this population accounted on average for a similar
proportion of the total HIV-1-specific CD8
+ T-cell responses in
both cohorts. Among the HIV-1-specific CD8
+ T-cells responding
to peptide stimulation, 43% and 39% were triple-positive in LTTS
and LTNPs, respectively (P=0.12). However, we observed a large
variability in the level of polyfunctionality which ranged from 82%
to 16% in LTTS and from 78% to 2% in LTNPs. We further
analysed our data in order to verify if HIV-1-specific CD8
+ T-cell
responses with high or low proportions of triple-positive cells were
detected in different subjects or within the same subjects. In other
words, we assessed whether various individuals had different
patterns of functional profiles or if responses with different
functional profiles could be detected within the same individual.
To address this issue, we analysed the level of polyfunctionality per
subject (Figure 4C) and found that most subjects showed responses
clustering within similar levels of triple-positive cells (i.e. LTNP
subject #10 vs. #13). However, in a few patients responses
differed in terms of the levels of triple-positive cells (i.e. LTNP
subject #6) showing different levels of polyfunctionality of HIV-1-
specific CD8
+ T-cell responses within the same subject.
Taken together, these data demonstrate that LTTS and LTNPs
display comparable levels of polyfunctional CD8
+ T-cell responses
and that factors independent of the group affiliation, i.e. LTTS or
LTNPs, are associated with the level of polyfunctionality.
Levels of HIV-1-specific CD8
+ T-cell polyfunctionality are
associated with the type of targeted epitope and HLA
class I restriction
Although an overall similar degree of HIV-1-specific CD8
+ T-
cells polyfunctionality was demonstrated in the LTTS and LTNP
groups, we found some variability in terms of some of the HIV-1-
specific CD8
+ T-cell responses in both groups. We therefore
attempted to characterize the factors that might explain these
different levels of polyfunctionality in two cohorts shown to have a
similar viral burden.
We first investigated whether the observed variability in
polyfunctionality was associated with the subjects’ clinical and
laboratory parameters, such as age, levels of CD4
+ and CD8
+ T-
cells, CD4
+/CD8
+ T-cell ratio, CD8
+/CD38
+ T-cell count, cell-
associated HIV-1 DNA and RNA in peripheral blood, and days
from diagnosis to ART initiation in LTTS. Based on simple
Figure 3. Comparison of the magnitude of HIV-1-specific CD8
+ T-cell responses between LTTS and LTNPs. Cumulative data (mean6SE)
of the percentage of IFN-c-, IL-2- and TNF-a-producing HIV-1 specific CD8
+ T-cells following 6 hours of in vitro stimulation with optimal CD8
+ T-cell
HIV-1 peptides (A) or with optimal CD8
+ T-cell Gag-derived peptides (B). LTTS: long-term treated HIV-1 seroconverters; LTNPs: HIV-1 long-term non-
progressors.
doi:10.1371/journal.pone.0018164.g003
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significantly associated with the proportion of triple-positive HIV-
1-specific CD8
+ T-cells except for the level of proviral DNA in
LTNPs. Of interest, levels of polyfunctionality and cell-associated
HIV-1 DNA were shown to be inversely correlated in this group
(P=0.016).
We then considered factors described to be associated with T-
cell polyfunctionality, such as the type of targeted viral region,
epitope and HLA class I restriction. With regard to the type of
targeted viral protein, responses against Gag have been associated
with a better clinical outcome [55], even in the absence of
protective HLA alleles [56]. As shown in Figure 5A, when
considering various functional HIV-1-specific CD8
+ T-cell
populations individually, we found some differences among viral
regions, however, the overall HIV-1-specific CD8
+ T-cell
functional profile did not differ according to the type of targeted
Figure 4. Functional cytokine profile of HIV-1-specific CD8
+ T-cells. (A) Cumulative data of the simultaneous analysis of IFN-c, IL-2 and TNF-a
production. All possible combinations of IFN-c, IL-2 and TNF-a production are shown on the x axis, whereas the percentage of the distinct cytokine-
producing cell subsets within HIV-specific CD8
+ T-cells is shown on the y axis. Pie charts (B) summarize the data and each slice corresponds to the
proportion of HIV-1 specific CD8
+ T-cells positive for a given combination of T-cell functions. (C) Per subject analysis of the proportion of CD8
+ T-cells
producing simultaneously 3 cytokines (IFN-c + IL-2 + TNF-a). All the responses identified are shown per subject and the mean of responses is shown
in red for each subject. Results from only 19 out of 20 LTTS subjects are shown as CD8
+ T-cell responses to optimal epitopes were not identified in
one subject, even though CD4
+ and CD8
+ T-cell responses upon stimulation with Gag peptide pool were detected. LTTS, long-term treated HIV-1
seroconverters; LTNPs: HIV-1 long-term non-progressors.
doi:10.1371/journal.pone.0018164.g004
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responses targeting Gag, Nef, Env or RT-Pol proteins (all P.0.1;
Figure 5A).
Recent data have also shown that the type of targeted epitope
plays an important role in shaping the functional profile of HIV-1-
specific CD8
+ T-cell response and that responses targeting
‘‘favourable epitopes’’ are correlated with good prognosis in terms
of viral control [57]. Accordingly, when pooling together all the
HIV-1-specific CD8
+ T-cell responses targeting ‘‘favourable
epitopes’’ (n=9) and comparing them to those that did not
(n=94), we found a different functional profile between the two
types of responses and a higher degree of polyfunctionality
associated with ‘‘favourable epitope’’-targeting responses (P=0.03;
Figure 5B). The mean proportion of triple-positive HIV-1-specific
CD8
+ T-cells was shown to be 51.47% for ‘‘favourable epitope’’
(range 12.26%–68.51%) and 39.72%for non-‘‘favourable epitope’’-
targeting responses (range 1.80%–81.58%) (P=0.02; Figure 5B).
Besides the type of targeted viral protein and epitope, HLA-B
restriction in general and HLA-B*5701 and B*2705 in particular
have been associated with better control of HIV-1 infection
[32,34,35,36,60,61,62]. Therefore, we analysed the level of
polyfunctionality based on the type of HLA class I-restriction in
our two cohorts. As shown in Figure 5C, HIV-1-specific CD8
+ T-
cell responses restricted by HLA-B alleles (n=59) did not display a
different functional profile compared to those restricted by HLA-A
or C (n=44; P.0.2). In contrast, as shown in Figure 5D, HIV-1-
specific CD8
+ T-cell responses restricted by HLA-B alleles
associated with slow HIV-1 disease progression (n=21) [37] were
significantly more polyfunctional than those which were not
(n=82; P=0.002) with a proportion of triple-positive CD8
+ T-
cells of 49% (range 37.86%–68.51%) versus 39%, respectively
(range 1.79%–81.58%; P=0.01). We found that HLA-B*5701-
restricted responses (n=15), in particular, were responsible for this
higher degree of polyfunctionality. In fact, when HLA-B*5701-
restricted responses were removed from the analysis, the difference
in functional profile was lost (P=0.4). It is thus possible to
hypothesize that the higher level of polyfunctionality shown for
responses targeting ‘‘favourable epitopes’’ was driven by the HLA-
B*5701 restriction since 55% of these responses (5 out of 9) were
HLA-B*5701-restricted.
Overall, our data demonstrate that the targeting of various viral
regions was associated with a similar HIV-1-specific CD8
+ T-cell
Figure 5. Analysis of HIV-1-specific CD8
+ T-cell polyfunctionality. Cumulative data of the analysis of simultaneous IFN-c, IL-2 and TNF-a
production comparing CD8
+ T-cell responses targeting distinct viral regions (A), targeting ‘favourable vs. ‘other than favourable’ epitopes (B),
restricted by HLA-B vs. HLA-A or -C alleles (C) and restricted by HLA class I alleles associated with slow disease progression (‘protective’) vs. all others
HLA class I alleles (D). All possible combinations of IFN-c, IL-2 and TNF-a production are shown on the x axis, whereas the percentage of each
cytokine-producing cell subset within HIV-specific CD8
+ T-cells is shown on the y axis. Only significant differences of a given virus-specific CD8
+ T-cell
response versus all others are shown. + denotes a P value ,0.05. Pie charts summarize the data, and each slice corresponds to the proportion of
virus-specific CD8
+ T-cells positive for a given combination of T-cell functions. LTTS: long-term treated HIV-1 seroconverters; LTNPs: HIV-1 long-term
non-progressors.
doi:10.1371/journal.pone.0018164.g005
Immuno-Virological Effects of Prolonged Early ART
PLoS ONE | www.plosone.org 10 April 2011 | Volume 6 | Issue 4 | e18164functional profile, whereas ‘‘favourable epitope’’-targeting and
HLA-B*5701 restriction were associated with a higher degree of
polyfunctionality.
Ex-vivo perforin expression is low and similar in both
cohorts
Cytotoxicity is the main mechanism by which CD8
+ T-cells
exert their antiviral activity with perforin as one of the most
important mediators of T-cell cytotoxicity [15]. Dysfunctional
perforin expression has been described at HIV seroconversion
[63], however, the impact of early and prolonged treatment on this
marker remains unknown. In order to compare perforin levels
between LTTS and LTNPs, we have analysed its ex-vivo
expression in a randomly selected subset of 24 subjects (14 LTTS
and 10 LTNPs). Seventy-one optimal epitope-specific CD8
+ T-cell
responses (31 in LTTS and 40 in LTNPs) were characterized
based on IFN-c, IL-2, TNF-a and perforin expression, using the
anti-perforin antibody clone B-D48 which is suitable for ICS
assays. A representative example is shown in Figure 6A. The
average perforin expression was found to be similarly low in both
cohorts, even though a trend for a higher expression in LTNPs was
observed: the mean percentage of virus-specific IFN-c
+ CD8
+ T-
cells expressing perforin was 0.031% (range 0.00%–0.40%) and
0.057% (range 0.00%–0.36%) in LTTS and LTNPs, respectively
(P=0.12). As shown in Figure 6B, the relative contribution of
perforin to the HIV-1-specific CD8
+ T-cell response was similar in
both cohorts: the mean proportion of HIV-1-specific CD8
+ T-cells
expressing perforin was 8% in LTTS and LTNPs (range 0.00%–
43.74% and 0.00%–48.26%, respectively; P=0.45).
In addition, we have found that the dominant virus-specific
CD8
+ T-cell populations were either perforin
2 and IL-2
2,o r
perforin
+ and IL-2
2, or IL-2
+ and perforin
2 (Figure 6B). This
observation confirms in HIV-1-specific CD8
+ T-cells our previous
observation in CMV-specific CD8
+ T-cell responses of the
divergent expression of perforin and IL-2, which is consistent
with their respective role in cytotoxic and proliferative capacities
[64].
Overall, we have demonstrated that under conditions of long-
term controlled viremia, either spontaneously or with antiretrovi-
ral treatment, perforin expression on HIV-1-specific CD8
+ T cells
was low. This finding is consistent with the low antigenic exposure
in both cohorts.
Discussion
We have comprehensively characterized T-cell responses in
peripheral blood in two cohorts with long-term controlled viremia
in the presence or absence of ART. As such we have addressed the
question of the impact of a prolonged period of successful treatment
initiated very early after HIV-1 seroconversion on HIV-1-specific
T-cell responses in a homogenous, laboratory-defined, single clinic-
based LTTS cohort with LTNPs as a comparator. Instead of the
conventionally used five parameters (i.e. IFN-c, TNF-a, IL-2, MIP-
1b and CD107a), we have focused on those which we believe are
most relevant to assess HIV-1 T-cell functionality (i.e. IFN-c, TNF-
a and IL-2) and have also included the assessment of perforin
expression in our analysis. Proliferative capacity and cytotoxicity
have been associated with IL-2 secretion and perforin expression,
respectively [9,15,32,51,52,64,65,66,67,68]. Thus our data provide
indirect information onthesetwokeyfunctions ofantiviralCD8
+ T-
cells. We have further characterized these two cohorts in terms of
levels of immune activation and viral burden.
The potential for the immune system to regenerate and avoid
the damage inflicted by chronic exposure to the virus and its
immunopathology with treatment initiation theoretically pro-
foundly differentiates the acute and chronic stages of HIV-1
infection, although early immune defects have been described
[63]. Short treatment periods at the time of seroconversion have
been associated with some degree of HIV-1-specific T-cell
preservation and reconstitution in terms of IFN-c-producing
HIV-1-specific T-cells [69]. The duration of ART-induced
aviremia and nadir CD4
+ T-cell levels have recently been shown
to be important factors for CD4
+ T-cell recovery, strongly
suggesting that the timing of ART initiation and its duration are
of crucial importance in terms of immune reconstitution [70]. This
is supported by evidence of immunovirological control upon ART
interruption in 5 HIV-infected individuals who had received very
early and prolonged treatment [71].
In contrast to some recent data describing that the recovery of
polyfunctionality, proliferation and cytotoxicity does not occur to
the same extent in aviremic subjects on ART initiated during the
chronic phase of the infection as in LTNPs [19], our results
demonstrate the presence of strong polyfunctional HIV-1-specific
CD4
+ and CD8
+ T-cell responses associated with low perforin
expression in HIV-1-specific CD8
+ T-cells in LTTS. These data
are consistent with a polyfunctional/non-cytotoxic profile in a
context of low viral burden as demonstrated by several virological
markers used in this study. Similar results were found in LTNPs,
although we observed a higher breadth and a trend towards a
higher magnitude of HIV-1-specific CD8
+ T-cell responses which
were mainly driven by strong anti-Gag responses. Extensive
demonstration has been made of the absence of correlation
between the magnitude and breadth of HIV-1-specific IFN-c-
producing T-cells and virological control in previous studies in
acute and chronic infection [72,73,74]. In contrast, several lines of
evidence point towards the fact that slow or non-progressive HIV-
1 infection, such as in LTNPs, is associated with polyfunctional
HIV-1-specific T-cell responses [6,9,10,74] as these have been
associated with virological control in several studies. Our results
therefore argue for a very substantial degree of immune
preservation/reconstitution of polyfunctional HIV-1-specific T-
cells with early and prolonged treatment initiation in association
with low viral burden.
However, causality cannot be inferred at this stage without
further evidence to prove that the type of polyfunctional HIV-1-
specific T-cell responses as described in our LTNP and LTT
cohorts is indeed one of the mechanisms by which virological
control is achieved. Some previous data have suggested that T-cell
functionality reflects antigen exposure rather than the mechanism
by which viremia is controlled due to the absence of polyfunctional
T-cells in some virological controllers, the possibility to induce
polyfunctional responses by ART and the virologic rebound upon
successful treatment cessation [21,51,52,66,75,76,77,78]. Howev-
er, beside its association with virological control in HIV-1
infection, a T-cell polyfunctional profile is indeed present in
HIV-2 infected subjects who have an overall better prognosis than
those with HIV-1 [79]. Other types of infection such as
coccidiomycosis and the mouse model of Leishmania major infection
have also shown association of control with polyfunctional T-cells
[80,81].
We are well aware that formal demonstration of the potential
impact of these responses on virological rebound in LTTS would
require treatment discontinuation. Previous trials with shorter
duration of ART initiated at the time of PHI have not shown
overall virological control except in few subjects. These subjects
might have controlled plasma viremia even in the absence of
treatment as it is not possible to exclude a LTNP/elite controller-
type of status at this stage of the infection [73]. If indeed viral
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initiation maintained over several years, it is tempting to imagine a
situation somewhat similar to minimal residual disease in
leukaemia whereby the immune system might be able to contain
the infection for prolonged periods of time in some patients as
recently described by Hocqueloux et al [71].
The results of the present study provide several important
insights into the features of HIV-specific CD8
+ T-cell responses in
subjects with low viral burden and long-term viral control in the
presence or absence of treatment. We have shown that HIV-1-
specific CD8
+ T-cell polyfunctionality was associated with the type
of targeted epitope and HLA restriction, both during natural
(LTNPs) and ART-induced (LTTS) viral control. Epitopes shown
to be associated with slow disease progression and HLA-B*5701-
restricted responses were associated with a higher degree of
polyfunctionality. In contrast, the level of polyfunctionality did not
differ among HIV-1-specific CD8
+ T-cell responses targeting
other viral proteins.
We have described in a previous study [15] that perforin
expression is modulated in vitro and in vivo by antigenic exposure.
Consistently, we have confirmed here that under conditions of
similar low viral burden the ex-vivo expression of perforin is low.
The trend for higher perforin expression in LTNPs as compared to
LTTS is in line with data from a recent study [22]. One could
speculate that the lower level of perforin observed in our LTTS
cohort was due to ART-mediated control of viremia in contrast to
LTNPs where further immune-based mechanisms may be needed
to control viremia in the absence of treatment. However, our data
do not allow us to formally exclude a residual decrease in perforin
expression in treated seroconverters, even after a prolonged ART
period.
The overall slightly lower levels of perforin expression by HIV-
1-specific CD8
+ T-cells observed in our study compared to those
found by Hersperger and colleagues [22] are possibly due to
differences in viral burden between the two cohorts as aviremia
might have been more prolonged in our LTNP subjects (11
subjects with permanent aviremia at ,50 and 4 subjects with
,1000 HIV-1 RNA copies/mL in at least 90% measurements
over 7 years vs. ,75 or ,50 HIV-1 RNA copies/mL in at least 3
measurements over 1 year, respectively). Consistent with the lower
perforin expression, IL-2 production was about four times higher
in our LTNP cohort compared with the other study. We [64] and
others [82] have indeed shown that IL-2 and perforin expression
by virus-specific CD8
+ T-cells is divergent.
We have added for comparative purposes between our two
cohorts further virological markers beside plasma viremia
Figure 6. HIV-1-specific CD8
+ T-cell perforin expression in LTTS and LTNPs. (A) Representative flow cytometric plots of perforin vs. IFN-c,
TNF-a and IL-2 expression are shown from one representative LTTS subject upon 6 hours in vitro stimulation with a Nef epitope, aa 73–82. (B)
Cumulative data of the simultaneous analysis of perforin, IFN-c, IL-2 and TNF-a expression. All possible combinations of perforin, IFN-c, IL-2 and TNF-a
expression are shown on the x axis, whereas the percentage of the various marker-expressing cell subsets within HIV-1 specific CD8
+ T-cells is shown
on the y axis. Only significant differences of a given virus-specific CD8
+ T-cell response versus all the others are shown. + denotes a P value,0.05. Pie
charts summarize the data, and each slice corresponds to the proportion of virus-specific CD8
+ T-cells positive for a certain combination of T-cell
functions. LTTS: long-term treated HIV-1 seroconverters; LTNPs: HIV-1 long-term non-progressors.
doi:10.1371/journal.pone.0018164.g006
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which are aimed at better characterizing viral burden in
peripheral blood. We could show that both cohorts were not
different in terms of cell-associated HIV-1 DNA and RNA levels in
blood, in contrast to what has recently been described in subjects
who had been treated in chronic infection for a similar duration as
our LTTS cohort [54]. However, caution should be applied in the
interpretation of viral reservoir levels in terms of viral rebound as it
might still occur upon treatment cessation even in patients with
extremely low viral burden [83]. The low level of reservoirs in
LTTS suggests that long-term ART is associated with a decrease
of their saturation overtime as previously described [42,84]
although we do not have longitudinal virological data from our
cohort to conclusively prove it and we have not investigated the
extent of gut reservoirs. Our results argue in favour of either an
incomplete saturation of reservoirs at the time of initiation of ART
at PHI or a more rapid decrease as compared to ART-treated
chronic infection as suggested by Chun et al [41].
In summary, our results demonstrate that subjects treated with
ART for several years at the time of seroconversion show great
similarity with LTNPs in terms of polyfunctional HIV-1-specific
T-cell responses, level of immune activation, residual viral
replication and saturation of HIV-1 reservoirs in peripheral blood.
These data should help define new types of interventions aimed at
optimizing ART timing and duration and implementing novel
therapeutic interventions in order to further deplete peripheral
reservoirs, enhance protective cellular immune responses and
promote virological control post-stopping treatment.
Supporting Information
Data S1 Gating strategy for identification of CD4
+ and
CD8
+ T-cells. Shown is a representative example of HIV-1 Gag-
specific responses from LTTS subject JIM-014 upon 6-hour in vitro
stimulation with the Gag peptide pool. This figure illustrates the
gating strategy used in the comprehensive analysis of cytokine
production and cytotoxic capacity as measured by IFN-c, IL-2 and
TNF-a production and perforin expression, respectively, in the
ICS assay. After initial gating on lymphocytes using forward and
side scatter properties, gating on forward scatter area (FSC-A)
versus height (FSC-H) was used to remove doublets. Events were
further gated on IFN-c versus the dead cell marker to remove dead
cells. CD3
+ T-cells were gated on the remaining live cells.
CD3
+CD8
+ T-cells were selected based on CD8
+ staining and
CD4
+ T-cells were then excluded. Cells within these individual
response gates were then entered into Boolean gating analysis to
generate frequencies for all possible combinations (i.e., positive or
negative) of the distinct functions (FlowJo software, version 8.8.2;
TreeStar). LTTS: long-term treated HIV-1 seroconverters;
LTNPs: HIV-1 long-term non-progressors.
(PPT)
Data S2 Analysis of the magnitude of HIV-1-specific
CD8
+ T-cell responses. (A) Cumulative data (mean6SE) on
the percentage of IFN-c-, IL-2- and TNF-a-producing HIV-1
specific CD8
+ T-cells following 6 hours of in vitro stimulation with
‘favourable’ epitopes (i.e. optimal CD8
+ T-cell epitopes known to
be associated with good viral control). (B) Cumulative data
(mean6SE) on the percentage of IFN-c, IL-2 and TNF-a
production in HLA-B*5701-restricted CD8
+ T-cell responses.
LTTS: long-term treated HIV-1 seroconverters; LTNPs: HIV-1
long-term non-progressors.
(PPT)
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